Search

everythinglearnresearchcommunity

for

Search:↓

More research is needed to find the best treatment for dissecting cellulitis of the scalp.

Corticosteroids are the most common treatment for alopecia areata, but many patients need better options.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Apremilast shows promise for several skin conditions but needs more research.

Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.

A child with low platelets and anemia was later found to have lupus.

A man with Isaac's syndrome affecting only one side of his body improved after immune system-targeted treatment.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

About 8% of people with systemic lupus erythematosus have chronic scarring alopecia, with certain symptoms and positive antibodies increasing the risk, while immunosuppressants may lower it.

The analysis aims to identify the most effective and safest treatments for alopecia areata.

A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.

Alopecia Areata is an autoimmune hair loss condition, with various treatments showing mixed effectiveness and no guaranteed cure.

Telogen Effluvium is a common hair loss condition that can be short-term or long-lasting and is often caused by stress, illness, or nutritional issues.

Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.

A patient with Cronkhite-Canada syndrome improved with nutritional support and steroids, but early diagnosis is key due to high mortality.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

The document concludes that the skin is a complex organ providing protection, sensation, and healing, with challenges in treating conditions like itchiness.

The document concludes that early diagnosis and treatment are crucial for managing rare hair loss disorders and that more research is needed to improve treatment strategies.

The conclusion is that maintaining blinding in clinical trials is crucial for reliable results.

Troglitazone increases subcutaneous fat in lipodystrophy patients.

The document concludes that there is no credible evidence that distant healing works, and it should not be further studied in medical literature.

Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.

Latanoprost is more effective than minoxidil for treating alopecia areata.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

AA patients with comorbid conditions face more severe hair loss and need specific treatments.

Kidney transplant patients often have skin issues, mainly infections.

A 50-year-old woman with breast cancer developed an autoimmune skin disorder, highlighting the need for thorough checks and team-based treatment.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Alopecia areata causes sudden hair loss, has genetic links, and can be managed but not cured.

Fever and rash can be early signs of lupus.